Loading...
•
Dec 31, 2019
Ultragenyx Q4 2019 Earnings Report
Ultragenyx reported financial results for Q4 2019 and reaffirmed its financial guidance for 2020.
Key Takeaways
Ultragenyx reported total revenue of $35.6 million for the fourth quarter of 2019. The company's net loss for the quarter was $93.8 million, or $1.62 per share.
Total revenue for Q4 2019 was $35.6 million.
Crysvita revenue totaled $29.9 million, including $26.1 million in U.S. collaboration revenue and $2.2 million in European royalty revenue.
Mepsevii product revenue was $4.4 million.
Net loss for Q4 2019 was $93.8 million, or $1.62 per share.
Revenue by Segment
Forward Guidance
The company continues to expect Crysvita revenue in the Ultragenyx territories to be between $125 million and $140 million in 2020 and expects a more than 20 percent reduction in net cash burn in 2020 compared to 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...